Home  |  Site Map  | Contact
 
Aug. 9

QLT Announces Second Quarter 2016 Results

   
Jun.17

QLT Announces Results of Annual General Meeting of Shareholders

   
jun. 15

Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger

   
May. 5

QLT Announces First Quarter 2016 Results

   
May. 2

QLT Terminates $20 Million Private Placement

   
   
   
   
   
   
   
   
   
   
  To view the "Aegerion and QLT Merger - A Compelling Rare Disease Opportunity" presentation click here
   
 

To view the “Clinical Proof-of-Concept Study of Oral Synthetic cis-Retinoid (QLT091001) In Adult Subjects with Impaired Dark Adaptation and/or Impaired Low Luminance Vision” presentation, presented at The ARVO 2015 Annual Meeting, Denver, Colorado, May 3-7, 2015, click here.
 
 
To view the “Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT” presentation, presented at The ARVO 2015 Annual Meeting, Denver, Colorado, May 3-7, 2015, click here.
   
 
2015 Annual Report
For the Annual Report for the fiscal year ended December 31, 2015, click here.
   
   
   
   
   
   
 
HEAD OFFICE: QLT Inc., 887 Great Northern Way, Suite 250, Vancouver, BC, Canada, V5T 4T5 | t 1.877.764.3131
Copyright © 2000-2015 QLT Inc. Legal Terms for use of site and Privacy Policy | Disclaimer
Vancouver Web Design by Graphically Speaking
 
Employee Login
 
'ss